OC
BLUE

Oppenheimer & Co’s bluebird bio BLUE Stock Holding History

Oppenheimer & Co’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-898
Closed -$372K – 1494
2021
Q2 		$372K Buy
+898
New +$356K 0.01% 1147
2021
Q1 		– Sell
-373
Closed -$209K – 1438
2020
Q4 		$209K Buy
373
+76
+26% +$48.2K ﹤0.01% 1231
2020
Q3 		$208K Buy
297
+44
+17% +$34.3K 0.01% 1137
2020
Q2 		$200K Buy
+253
New +$191K 0.01% 1123
2019
Q3 		– Sell
-137
Closed -$226K – 1270
2019
Q2 		$226K Hold
137
– – 0.01% 1132
2019
Q1 		$280K Buy
+137
New +$241K 0.01% 1065

Other funds holding BLUE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

Oppenheimer & Co's BLUE Position: Q3 2021 in Review

Oppenheimer & Co sold out of bluebird bio (BLUE) in Q3 2021, closing a stake of 898 shares — an estimated $372K sold.

Oppenheimer & Co first reported a position in BLUE in Q1 2019 and held it in 6 quarters. The position peaked at $372K in Q2 2021. 196 funds tracked by Wall St. Rank hold BLUE as of Q3 2021.

  • Oppenheimer & Co reported no remaining bluebird bio position as of Q3 2021 after selling out during the quarter.
  • Oppenheimer & Co sold 898 bluebird bio shares in Q3 2021, an estimated $372K.
  • Oppenheimer & Co first reported a position in bluebird bio in Q1 2019 and held it in 6 quarters.
  • Oppenheimer & Co's bluebird bio position peaked at $372K in Q2 2021.
  • 196 funds tracked by Wall St. Rank held bluebird bio as of Q3 2021.

Based on Oppenheimer & Co's 13F filing for Q3 2021, filed 12 Nov 2021.